Scipher Medicine Unveils New Tool to Predict Rheumatoid Arthritis Treatment Success at EULAR 2025
WALTHAM, Mass.--(BUSINESS WIRE)--At the European Congress of Rheumatology (EULAR) 2025, Scipher Medicine, the company behind the groundbreaking PrismRA ® test, unveiled a new, AI-driven approach to help doctors better evaluate if a rheumatoid arthritis (RA) treatment is truly working — a challenge that has long frustrated both patients and physicians.
This new 'RA Response Calculator,' developed using real-world patient data and machine learning, offers a more accurate way to determine whether someone is actually improving on their current therapy — cutting through the noise of subjective measures like patient self-reports and physician assessments.
'Anyone living with RA knows that figuring out whether a medication is working can take months — and even then, it's often unclear,' said Reg Seeto, CEO of Scipher Medicine. 'We created this tool to make that process faster, clearer, and more personalized. It brings science and objectivity to a space that's long relied on educated guesswork.'
The study analyzed data from nearly 1,500 RA patients receiving commonly prescribed treatments — TNF inhibitors, T-cell inhibitors, and IL-6 inhibitors. By applying a machine learning algorithm to joint tenderness, swelling, and inflammation data collected over 24 weeks, Scipher's team identified a combination of two standard clinical measures that best predicts therapy success: Tender Joint Count (TJC) and Swollen Joint Count (SJC).
The result: a simple formula that predicts whether a treatment is helping — or if it's time to try something else.
'Doctors already use TJC and SJC in the clinic. What's new is how we've mathematically combined them using real-world data and AI to create a consistent, data-backed benchmark for treatment response,' said Seeto. 'This is about giving providers and patients a clearer, faster answer — and a better shot at remission.'
The new tool also showed improved accuracy over standard response metrics like CDAI and ACR scores, which are commonly used in trials but often fall short in real-world care.
About Scipher Medicine
Scipher Medicine is transforming how autoimmune diseases like RA are treated by using AI and network biology to match patients with therapies that actually work. Through its SPECTRA Rx and Dx platforms, Scipher combines the largest clinico-genomic dataset in rheumatology with real-world medical records, creating powerful tools to personalize care and improve drug development. Learn more at www.sciphermedicine.com.
PrismRA is a first-of-its-kind blood test that helps doctors identify which RA patients are unlikely to respond to TNF inhibitor therapy — the most commonly prescribed (and most expensive) class of RA drugs. With just a routine blood draw, PrismRA analyzes a patient's molecular signature to guide more effective and personalized treatment plans. Visit PrismRA.com to learn more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
6 minutes ago
- Miami Herald
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows. As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps. "The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses." NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption. More information on how to order and additional ZeptoMetrix products can be found at: About ZeptoMetrix® ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials. Product Page: Contact Information Andrew Zenger Global Product 715-7417 SOURCE: ZeptoMetrix press release
Yahoo
9 minutes ago
- Yahoo
Students Using Lexia Core5 Reading Outperformed Their Peers On the Smarter Balanced English Language Arts/Literacy Assessment
New Lexia Study Examines Performance of More Than 1 Million California Students to Ascertain the Impact of Literacy Program BOSTON, June 23, 2025--(BUSINESS WIRE)--In California, third- to fifth-grade students at 525 schools using Lexia Core5 Reading (Core5) from Lexia, a Cambium Learning Group brand, made significantly higher literacy gains compared to their peers in 4,362 schools that did not use the program. The schools were highlighted in a recently released report which compared the students' performance on the Smarter Balanced English Language Arts/Literacy (SBAC ELA) assessment. Core5 accelerates the foundational and advanced literacy skills for all students—from at-risk to on-level and advanced—in elementary grades. The research-proven program provides students with a systematic and structured approach to phonological awareness, oral language, phonics, vocabulary, fluency, and comprehension. "This study is the first to investigate the impact of Core5 at scale in California schools," said Lexia President Nick Gaehde. "Our study evaluated Core5's impact on more than one million California elementary students' ELA achievement during the 2022-23 school year. We started with third graders because they are the youngest students assessed on the Smarter Balanced assessment." The Core5 and non-Core5 schools in the study had similar average scores on the 2022 SBAC ELA. However, on the 2023 assessment, third graders at the Core5 schools scored an average of 3.49 points higher than their peers at the non-Core5 schools. The scores for Core5-using fourth and fifth graders were, on average, 2.81 and 3.35 points higher respectively than their non-using peers. The Core5 schools had more Emergent Bilingual students as well as more Hispanic or Latino students than non-Core5 schools. However, both categories of schools were similar in total enrollment and the percentage of students receiving free or reduced-price lunch. "Interestingly, third and fourth grade students at the schools using Core5 also scored statistically higher—3.08 points and 3.04 points higher, respectively—on the SBAC Math assessment than students at non-Core5 schools," said Gaehde. "That fact drives home the point that improving students' literacy outcomes boosts their achievements in other areas. Since post-pandemic federal relief funds expired in 2024, school leaders have had to decide whether they should continue investing in interventional programs. These results show that Core5 is helping California educators address the critical need to improve student reading proficiency." About LexiaLexia®, a Cambium Learning® Group brand, is transforming literacy education, driving change in 1 of every 3 school districts across the United States. For more than 40 years, Lexia has been a thought leader in literacy education, delivering award-winning, research-based solutions grounded in the science of reading. With a full spectrum of offerings, including professional learning, curriculum, and embedded assessment tools, Lexia provides educators with Structured Literacy solutions that are proven effective and designed to drive meaningful literacy outcomes. By empowering educators with unparalleled ease of use and the knowledge and tools they need, Lexia helps more students unlock their potential to read, write, and speak with confidence. For more information, visit About Cambium Learning GroupCambium Learning Group is the education essentials company, providing award-winning education technology and services for K-12 educators and students. With an intentional collection of respected global brands, Cambium serves as a leader, helping millions of educators and students feel more seen, valued, and supported every day. In everything it does, the company focuses on the elements that are most essential to the success of education, delivering simpler, more certain solutions that make a meaningful difference right now. To learn more, visit or follow Cambium on Facebook, LinkedIn, and X. The Cambium family of brands includes: Cambium Assessment®, Lexia®, Learning A-Z®, ExploreLearning®, and Time4Learning®. View source version on Contacts Media Contacts Sabrina Leon, Lexia PR Charlotte Andrist, Nickel Communicationscharlotte@ Media Inquiries Only: 770-310-5244
Business Wire
an hour ago
- Business Wire
New Study from Marathon Health Reveals Advanced Primary Care Yields Immediate ROI and Curbs Acute Care Use
INDIANAPOLIS--(BUSINESS WIRE)-- Marathon Health, a leading provider of advanced primary care (APC) for employers and unions across the United States, has released a new large-scale claims study showing that APC — starting in year 1 of an employer's investment — significantly reduces health care costs, as employees engage in more preventive care and less acute/specialty care. The findings arrive at a critical moment: The 2025 Milliman Medical Index reports health care costs for a family of four have reached $35,119 in the typical employer-sponsored health plan, up 188% over the 20 years of the study. This far outpaces wage growth and inflation, putting increasing pressure on employee and plan sponsor budgets. 'Advanced primary care is a 21st-century approach rooted in decades of evidence,' says Dr. Nirav Vakharia, chief health officer at Marathon Health and a practicing primary care physician. 'For more than 50 years, research has shown that strong primary care leads to better clinical outcomes, less unnecessary utilization, and lower costs. What sets advanced primary care apart is that it doesn't reinvent the fundamentals — it delivers them with greater consistency through timely access, continuity between patients and providers, and whole-person care. That's how we create a health care system that truly works for working Americans.' Part of Marathon Health's ongoing and rigorous assessment of return on investment (ROI), the study examined over 3 million medical claim records across two cohorts — 89,000 members among 29 sponsors over five years; 224,000 members among 60 sponsors — via a methodology independently assessed by Milliman. Key findings under the most conservative of assumptions, including around engagement rates, show: Marathon Health's APC model pays for itself in the first year and delivers 3.7x ROI by year 5 Engaged members utilize more preventive care and less downstream acute care, and have: 21% lower claims costs 82% higher primary care utilization 15% fewer emergency room visits 41% fewer inpatient admissions The results reinforce APC's power to reduce unnecessary or avoidable high-cost care by encouraging prevention and early intervention — and employers have taken note. Advanced primary care adoption is rapidly accelerating: 76% of purchasers are currently offering APC or are considering adoption within the next 1-3 years, according to the National Alliance of Healthcare Purchaser Coalitions. Marathon Health will be hosting a public webinar on the study and its implications on June 26, 2025. Register here: To access the full study, visit About Marathon Health Marathon Health is a leading advanced primary care provider, partnering with employer and union plan sponsors to improve health for millions of Americans. With nationwide onsite, nearsite, and network health centers, and virtual primary care, Marathon delivers a value-based model that enhances the health care experience for members and providers, while driving meaningful cost savings for plan sponsors. Learn more at
